Corient Private Wealth LLC Has $569,000 Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

Corient Private Wealth LLC trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX) by 50.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 222,380 shares of the company’s stock after selling 224,080 shares during the quarter. Corient Private Wealth LLC’s holdings in ImmunityBio were worth $569,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. State Street Corp lifted its position in ImmunityBio by 10.1% during the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after acquiring an additional 790,408 shares during the last quarter. Barclays PLC lifted its position in shares of ImmunityBio by 127.4% during the 3rd quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after purchasing an additional 202,248 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in ImmunityBio by 71.2% during the 4th quarter. Handelsbanken Fonder AB now owns 92,300 shares of the company’s stock valued at $236,000 after purchasing an additional 38,400 shares during the period. SBI Securities Co. Ltd. acquired a new stake in ImmunityBio in the 4th quarter valued at approximately $58,000. Finally, Stephens Inc. AR bought a new position in ImmunityBio in the 4th quarter worth approximately $26,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Price Performance

Shares of IBRX stock opened at $3.14 on Friday. ImmunityBio, Inc. has a one year low of $2.28 and a one year high of $10.53. The stock has a fifty day moving average price of $3.13 and a 200 day moving average price of $3.60. The stock has a market cap of $2.68 billion, a P/E ratio of -3.41 and a beta of 0.82.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.11. The business had revenue of $7.55 million during the quarter, compared to analyst estimates of $8.74 million. Equities research analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Analysts Set New Price Targets

IBRX has been the topic of several research analyst reports. BTIG Research initiated coverage on shares of ImmunityBio in a research note on Friday, January 10th. They issued a “buy” rating and a $6.00 price objective on the stock. D. Boral Capital reissued a “buy” rating and issued a $30.00 price target on shares of ImmunityBio in a report on Thursday, March 13th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of ImmunityBio in a report on Thursday, March 13th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $12.19.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.